Phase 4 N=11 Acetazolamide Challenge With Perfusion in the Prediction of Cerebral Vasospasm
Subarachnoid Hemorrhage, Aneurysmal · Vasospasm, Cerebral
Primary: Number of Participants Who Develop Delayed Cerebral Vasospasm — 2 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=10 Safety Study of Dantrolene to Treat Cerebral Vasospasm After Subarachnoid Hemorrhage
Cerebral Vasospasm After Subarachnoid Hemorrhage
Primary: Hemodynamic Parameters (Change From Baseline Systolic Blood Pressure (Pre-infusion) Over Time Until 135 Minutes Post-infusion) — -8; -3.4 mmHg
N/A N=30 Vesalio NeVa VS for Symptomatic Cerebral Vasospasm Following aSAH (The VITAL Study)
Cerebral Vasospasm
Primary: Procedural Success — 64 Vessels Treated
Phase 3 N=409 Clinical Research Study With Clazosentan to Evaluate Its Effects on Preventing Complications Due to the Narrowing of the Blood Vessels (Vasospasm) in the Brain, Caused by Bleeding Onto the Surface of the Brain
Aneurysmal Subarachnoid Hemorrhage
Primary: Occurrence of Clinical Deterioration Due to Delayed Cerebral Ischemia (DCI) From Study Drug Initiation up to 14 Days Post-study Drug Initiation — 32; 35 Participants…
Phase 2 N=19 Safety and Pharmacokinetic Evaluation of Nitrite for Prevention of Cerebral Vasospasm
Subarachnoid Hemorrhage
Primary: Mean Plasma Nitrite Concentration (Micromol/L) — 4.2; 4.3; 2.6 micromol/L
Phase 2 N=31 Safety Study of Dantrolene in Subarachnoid Hemorrhage
Subarachnoid Hemorrhage · Cerebral Vasospasm
Primary: Hyponatremia — 7; 10 participants
Phase 2 N=56 Effect of Red Blood Cell Transfusion on Brain Metabolism in Patients With Subarachnoid Hemorrhage
Subarachnoid Hemorrhage · Vasospasm
Primary: Change in Oxygen Delivery in Vulnerable Brain Regions — 3.7; 4.3 ml/100g/min — p=0.001
Phase 3 N=225 Diagnosis and Treatment of Sleep Apnea in Cerebrovascular Disease
Obstructive Sleep Apnea · Stroke · Transient Ischemic Attack
Primary: Sleep Apnea Diagnosis Rate — 58; 5 participants
Phase 2 N=42 Statins and Cerebral Blood Flow in Subarachnoid Hemorrhage (SAH)
Subarachnoid Hemorrhage
Primary: Resting Cerebral Blood Flow During Peak Period of Vasospasm Risk — .34; .30 mL/100 g/min
N/A N=96 Vasopressin Versus Catecholamines for Cerebral Perfusion Pressure Control in Brain Injured Trauma Patients
Traumatic Brain Injury
Primary: Time ICP >20 — 1.7; .9 Hours
N/A N=460 Cerebral Autoregulation Monitoring During Cardiac Surgery
Thoracic Surgery · Cardiopulmonary Bypass
Primary: Composite Neurological Outcome of Clinical Stroke or New Ischemic Brain Lesion on Diffusion Weighted MRI or Neurocognitive Dysfunction 4 to 6 Weeks After Surgery. — 79…
Phase 2 N=31 NeuroCognition After Carotid Recanalization
Cognition Disorder · Stroke · Occlusion Carotid
Primary: Change in Montreal Cognitive Assessment (MoCA) Score — 0.56; 1.38; -0.75; 0.50 score on a scale
N/A N=126 Quantifying Collateral Perfusion in Cerebrovascular Disease-Moyamoya Disease and Stroke Patients
Cerebrovascular Accident · Moyamoya Disease
Primary: Percentage of Regions With Collateral Versus Antegrade Blood Flow (Sensitivity) Correctly Identified Using MRI With Xenon Contrast Agent (Specificity) — 81.7; 88.9…
Phase 2 N=30 Induced Suppression of Platelets Activity in Aneurysmal SAH Management (iSPASM)
Subarachnoid Hemorrhage, Aneurysmal
Primary: Number of Participants With Intracranial Hemorrhage (Symptomatic and Asymptomatic) — 2; 1 Participants
N/A N=52 Surgical Indirect Revascularization For Symptomatic Intracranial Arterial Stenosis
Intracranial Arterial Stenosis · Intracranial Atherosclerosis · Ischemic Stroke
Primary: Stroke or Death in the Territory of Qualifying Artery — 5 Participants — p=0.08
Phase 1 N=20 Reperfusion With Cooling in Cerebral Acute Ischemia
Stroke, Acute
Primary: Number of Participants With Reperfusion Injury Hemorrhagic Transformation — 3 participants
Phase 4 N=150 The Role of Verapamil in Radial Artery Spasm
Radial Artery Spasm
Primary: Number of Participants With Clinical Radial Artery Spasm (RAS) — 23; 3 participants
Phase 4 N=203 Effect of Cilostazol in the Acute Lacunar Infarction Based on Pulsatility Index of Transcranial Doppler
Cerebral Infarction
Primary: The Changes of Middle Cerebral Artery (MCA) and Basilar Artery (BA) Pulsatility Index (PI) at 14 and 90 Days From the Baseline Transcranial Doppler (TCD) Study — 0.07…
Phase 2 N=21 The Effects of Normalizing Blood Pressure on Cerebral Blood Flow in Hypotensive Individuals With Spinal Cord Injury
Spinal Cord Injury · Autonomic Dysreflexia · Baroreceptor Integrity
Primary: Systolic Blood Pressure — 93.21; 107.00; 95.8; 93.84 mmHg
N/A N=34 Preconditioning for Aneurismal Subarachnoid Hemorrhage
Subarachnoid Hemorrhage
Primary: Number of Patients With Deep Vein Thrombosis for Safety Assessment. — 0; 3; 0; 0 participants
N/A N=60 Cerebral Blood Perfusion Changes After General Anesthesia for Craniotomy
Brain Neoplasms · Surgery · Hyperemia
Primary: Mean Blood Flow Velocity in Middle Cerebral Artery — 63.7; 61.8 cm/s — p=0.554
Phase 4 N=457 Trial of Cilostazol in Symptomatic Intracranial Arterial Stenosis II
Cerebral Infarction · Atherosclerosis
Primary: Number of Participants With Progression of Symptomatic Intracranial Stenosis — 20; 32 participants
N/A N=37 Ventriculostomies in SAH: ICP Open or Not?
Subarachnoid Hemorrhage
Primary: Cerebral Artery Vasospasm — 16; 7 Participants
Phase 3 N=19 Blood Pressure, Cerebral Blood Flow and Cognition in Spinal Cord Injury
Spinal Cord Injury
Primary: Systolic Blood Pressure — 116.3; 98.0 mmHg
Phase 2 N=185 Evaluating Neuroprotection in Aneurysm Coiling Therapy
Stroke
Primary: Volume of New FLAIR Lesions(MRI) — 915; 477 mm^3 — p=0.445
Phase 2 N=120 Blood Pressure After Endovascular Stroke Therapy-II
Acute Stroke · Endovascular Thrombectomy
Primary: Final Infarct Volume — 46.4; 50.7; 32.4 Cubic Centimeters
Phase 1 N=60 Antihypertensive Treatment in Acute Cerebral Hemorrhage
Intracerebral Hemorrhage · Hypertension · Stroke
Primary: Particpants Who Achieve and Maintain the Systolic Blood Pressure Goals for Each Treatment Tier. — 18; 20; 22; 7 participants — p=< 0.01
Phase 3 N=451 Stenting vs. Aggressive Medical Management for Preventing Recurrent Stroke in Intracranial Stenosis
Ischemic Stroke
Primary: Any Stroke or Death Within 30 Days of Enrollment or Any Revascularization Procedure OR an Ischemic Stroke in the Territory of the Symptomatic Intracranial Artery Beyond…
Phase 2 N=92 The Spot Sign for Predicting and Treating ICH Growth Study
Intracerebral Hemorrhage
Primary: Number of Study Subjects With Life-threatening Thromboembolic Complications — 1; 0; 0 Participants — p=1.00
Phase 2 N=36 Study Evaluating the Safety,Tolerability and Efficacy of PF-04360365 in Adults With Probable Cerebral Amyloid Angiopathy
Cerebral Amyloid Angiopathy
Primary: Change From Baseline to Day 2 in Cerebrovascular Reactivity as Measured by the Slope (Amplitude Over Time to Peak) From Visual Task-evoked Functional Magnetic Resonance…